Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26945058
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deep RNA profiling identified CLOCK and molecular clock genes as
pathophysiological signatures in collagen VI myopathy
#MMPMID26945058
Scotton C
; Bovolenta M
; Schwartz E
; Falzarano MS
; Martoni E
; Passarelli C
; Armaroli A
; Osman H
; Rodolico C
; Messina S
; Pegoraro E
; D'Amico A
; Bertini E
; Gualandi F
; Neri M
; Selvatici R
; Boffi P
; Maioli MA
; Lochmüller H
; Straub V
; Bushby K
; Castrignanò T
; Pesole G
; Sabatelli P
; Merlini L
; Braghetta P
; Bonaldo P
; Bernardi P
; Foley R
; Cirak S
; Zaharieva I
; Muntoni F
; Capitanio D
; Gelfi C
; Kotelnikova E
; Yuryev A
; Lebowitz M
; Zhang X
; Hodge BA
; Esser KA
; Ferlini A
J Cell Sci
2016[Apr]; 129
(8
): 1671-84
PMID26945058
show ga
Collagen VI myopathies are genetic disorders caused by mutations in collagen 6
A1, A2 and A3 genes, ranging from the severe Ullrich congenital muscular
dystrophy to the milder Bethlem myopathy, which is recapitulated by
collagen-VI-null (Col6a1(-/-)) mice. Abnormalities in mitochondria and autophagic
pathway have been proposed as pathogenic causes of collagen VI myopathies, but
the link between collagen VI defects and these metabolic circuits remains
unknown. To unravel the expression profiling perturbation in muscles with
collagen VI myopathies, we performed a deep RNA profiling in both Col6a1(-/-)mice
and patients with collagen VI pathology. The interactome map identified common
pathways suggesting a previously undetected connection between circadian genes
and collagen VI pathology. Intriguingly, Bmal1(-/-)(also known as Arntl) mice, a
well-characterized model displaying arrhythmic circadian rhythms, showed profound
deregulation of the collagen VI pathway and of autophagy-related genes. The
involvement of circadian rhythms in collagen VI myopathies is new and links
autophagy and mitochondrial abnormalities. It also opens new avenues for
therapies of hereditary myopathies to modulate the molecular clock or potential
gene-environment interactions that might modify muscle damage pathogenesis.